Zacks Research Issues Pessimistic Estimate for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Investment analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.38) per share for the quarter, down from their previous estimate of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.57) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.75) EPS.

ALLO has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler reduced their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.73.

Allogene Therapeutics Price Performance

ALLO opened at $2.06 on Monday. The firm has a market cap of $431.92 million, a PE ratio of -1.32 and a beta of 0.86. The stock has a 50-day moving average price of $2.32 and a 200-day moving average price of $2.54. Allogene Therapeutics has a 1 year low of $1.78 and a 1 year high of $5.78.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its stake in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company’s stock worth $1,361,000 after purchasing an additional 5,642 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Allogene Therapeutics by 2.1% during the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock valued at $986,000 after buying an additional 9,635 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock valued at $95,000 after acquiring an additional 10,855 shares during the period. Private Advisor Group LLC bought a new position in shares of Allogene Therapeutics during the 3rd quarter valued at approximately $34,000. Finally, Federated Hermes Inc. purchased a new stake in Allogene Therapeutics in the 2nd quarter worth approximately $29,000. 83.63% of the stock is currently owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).